blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2856149

EP2856149 - DIABETES BIOMARKERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.05.2021
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  11.09.2019
FormerExamination is in progress
Status updated on  02.08.2019
FormerGrant of patent is intended
Status updated on  10.12.2018
FormerExamination is in progress
Status updated on  15.09.2017
FormerRequest for examination was made
Status updated on  12.01.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Phaim Pharma Ltd
One Bartholomew Close
London EC1A 7BL / GB
[2021/01]
Former [2017/50]For all designated states
DMNoMore
266 Fulham Road
London House Suite 19
London
SW10 9EL / GB
Former [2015/15]For all designated states
Orban Biotech LLC
64 Aspinwall Avenue 1
Brookline, MA 02446 / US
Inventor(s)01 / ORBAN, Tihamer
64 Aspinwall Avenue no.1
Brookline, MA 02446 / US
 [2020/28]
Former [2015/15]01 / ORBAN, Tihamer
64 Aspinwall Avenue 1
Brookline, MA 02446 / US
Representative(s)Dehns
10 Old Bailey
London EC4M 7NG / GB
[N/P]
Former [2020/28]Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
Former [2015/15]Gardner, Rebecca Katherine
Dehns
St Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
Application number, filing date13794110.024.05.2013
[2020/28]
WO2013US42627
Priority number, dateUS201261651144P24.05.2012         Original published format: US 201261651144 P
[2015/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013177505
Date:28.11.2013
Language:EN
[2013/48]
Type: A1 Application with search report 
No.:EP2856149
Date:08.04.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 28.11.2013 takes the place of the publication of the European patent application.
[2015/15]
Type: B1 Patent specification 
No.:EP2856149
Date:08.07.2020
Language:EN
[2020/28]
Search report(s)International search report - published on:RU28.11.2013
(Supplementary) European search report - dispatched on:EP03.05.2016
ClassificationIPC:G01N33/48, G01N33/564
[2016/22]
CPC:
G01N33/505 (EP); G01N33/5094 (US); A61P37/00 (EP);
A61P5/50 (EP); G01N33/564 (EP,US); G01N33/56972 (EP,US);
G01N33/6893 (EP); G01N2800/042 (EP,US); G01N2800/52 (EP,US) (-)
Former IPC [2015/15]G01N33/48, A61K45/00, A61P37/00, A61P5/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/15]
Extension statesBA23.12.2014
ME23.12.2014
TitleGerman:BIOMARKER FÜR DIABETES[2015/15]
English:DIABETES BIOMARKERS[2015/15]
French:BIOMARQUEURS DU DIABÈTE[2015/15]
Entry into regional phase23.12.2014National basic fee paid 
23.12.2014Search fee paid 
23.12.2014Designation fee(s) paid 
23.12.2014Examination fee paid 
Examination procedure23.12.2014Examination requested  [2015/15]
21.03.2017Amendment by applicant (claims and/or description)
18.09.2017Despatch of a communication from the examining division (Time limit: M04)
18.01.2018Reply to a communication from the examining division
11.12.2018Communication of intention to grant the patent
31.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.09.2019Communication of intention to grant the patent
28.02.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
07.05.2020Fee for grant paid
07.05.2020Fee for publishing/printing paid
07.05.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20184212.7  / EP3767295
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.09.2017
Opposition(s)09.04.2021No opposition filed within time limit [2021/24]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
07.05.2020Request for further processing filed
07.05.2020Full payment received (date of receipt of payment)
Request granted
18.05.2020Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
31.07.2019Request for further processing filed
31.07.2019Full payment received (date of receipt of payment)
Request granted
14.08.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
21.03.2017Request for further processing filed
21.03.2017Full payment received (date of receipt of payment)
Request granted
05.04.2017Decision despatched
Fees paidRenewal fee
24.11.2015Renewal fee patent year 03
19.05.2016Renewal fee patent year 04
30.05.2017Renewal fee patent year 05
18.05.2018Renewal fee patent year 06
17.05.2019Renewal fee patent year 07
27.05.2020Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.05.201503   M06   Fee paid on   24.11.2015
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.05.2013
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
TR08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
[2024/41]
Former [2024/29]HU24.05.2013
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
TR08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2024/22]HU24.05.2013
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2023/30]HU24.05.2013
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2023/29]HU24.05.2013
AL08.07.2020
AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2022/07]AL08.07.2020
AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/36]AL08.07.2020
AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/28]AL08.07.2020
AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/25]AL08.07.2020
AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/22]AT08.07.2020
CZ08.07.2020
EE08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/10]AT08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RS08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/09]AT08.07.2020
LT08.07.2020
BG08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/07]LT08.07.2020
Documents cited:Search[A]   MEHLING M ET AL: "FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 71, no. 16, 1 October 2008 (2008-10-01), pages 1261 - 1267, XP009165260, ISSN: 0028-3878, DOI: 10.1212/01.WNL.0000327609.57688.EA [A] 1-12 * abstract, fig. 2, discussion *

DOI:   http://dx.doi.org/10.1212/01.wnl.0000327609.57688.ea
 [A]   XIAOFANG ZHANG ET AL: "Acute Response of Peripheral Blood Cell to Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetic Patient", PLOS ONE, vol. 7, no. 2, 22 February 2012 (2012-02-22), pages e31887, XP055265186, DOI: 10.1371/journal.pone.0031887 [A] 1-12 * abstract, Tab. 2 and 3, final paragraph of the discussion *

DOI:   http://dx.doi.org/10.1371/journal.pone.0031887
 [A]   ELENA MATTEUCCI ET AL: "Altered Proportions of Nave, Central Memory and Terminally Differentiated Central Memory Subsets among CD4and CD8T Cells Expressing CD26 in Patients with Type 1 Diabetes", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 31, no. 6, 2 September 2011 (2011-09-02), pages 977 - 984, XP019983572, ISSN: 1573-2592, DOI: 10.1007/S10875-011-9573-Z [A] 1-12 * the whole document * * abstract, Tab. II, III *

DOI:   http://dx.doi.org/10.1007/s10875-011-9573-z
 [A]   TIHAMER ORBAN ET AL: "Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial", THE LANCET, vol. 378, no. 9789, 1 July 2011 (2011-07-01), GB, pages 412 - 419, XP055242611, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(11)60886-6 [A] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1016/S0140-6736(11)60886-6
 [T]   T. ORBAN ET AL: "Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline", DIABETES, vol. 63, no. 10, 16 May 2014 (2014-05-16), US, pages 3449 - 3457, XP055266767, ISSN: 0012-1797, DOI: 10.2337/db14-0047 [T] * the whole document *

DOI:   http://dx.doi.org/10.2337/db14-0047
International search[X] WO2009120341  (UNIV SOUTH FLORIDA et al.) [X]
 [Y]   ADAM KRETOWSKI ET AL.: "Ocena subpopulacji limfocyt6w T pomocniczych: naiwnych (CD4+CD45RA+), pamieci (CD4+CD45RO+) oraz wykazujacych ekspresje fenotyp6w CD45RA+ i CD45RO+ w przedklinicznej fazie cukrzycy typu 1 (prediabetes).", PRZEGLAG LEKARSKI, vol. 58, no. 1, 2001, pages 16 - 19, XP008175726 [Y]
 [Y]   BART O. ROEP.: "The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure", DIABETOLOGIA, vol. 46, no. 3, 2003, pages 305 - 321, XP055179757 [Y]

DOI:   http://dx.doi.org/10.1007/s00125-003-1089-5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.